Salahuddin Kaddoura, MD
Family Medicine · Fort Smith, ARNPI 1538102322
Payments from drug & device makers
Across 74 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$249
- AstraZeneca$128
- Novo Nordisk$109
- Amgen$106
- Pfizer$83
- Boehringer Ingelheim$48
- plus $351 from 14 others
What the payments were for
- Food & beverage$1,075100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $249 |
| AstraZeneca | 9 | $128 |
| Novo Nordisk | 6 | $109 |
| Amgen | 5 | $106 |
| Pfizer | 5 | $83 |
| Boehringer Ingelheim | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| GSK | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Exact Sciences | 2 | $34 |
| Lilly USA, LLC | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$1,075 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 277 | $209,208 |
| OzempicSemaglutide | 144 | $151,381 |
| MounjaroTirzepatide | 126 | $150,473 |
| JardianceEmpagliflozin | 142 | $114,999 |
| XareltoRivaroxaban | 88 | $77,264 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $72,102 |
| MyrbetriqMirabegron | 127 | $60,520 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $45,263 |
| LinzessLinaclotide | 57 | $41,699 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $36,731 |
| FarxigaDapagliflozin Propanediol | 51 | $32,442 |
| GemtesaVibegron | 47 | $29,444 |
| JanuviaSitagliptin Phosphate | 33 | $29,341 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $28,923 |
| TrulicityDulaglutide | 25 | $26,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $209,208277 claims |
| Lilly USA, LLCMounjaro, Trulicity | $24 | $177,458151 claims |
| Novo NordiskOzempic | $109 | $151,381144 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $48 | $138,481179 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta, Bevespi Aerosphere | $128 | $123,064216 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $43 | $106,986160 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $60,520127 claims |
| AbbVieLinzess | $249 | $41,69957 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Fort Smith
- Glenn GibbonsFort Smith$179K
- Thinh NguyenFort Smith$28K
- Allen BeachyFort Smith$21K
- Michael CallawayFort Smith$15K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.